Accueil   Diary - News   All news Poxel and Sumitomo Dainippon Pharma : new results for Imeglimin

Poxel and Sumitomo Dainippon Pharma : new results for Imeglimin

 

Poxel and Sumitomo Dainippon Pharma Announce Second Positive Top-Line Results for Imeglimin
Phase 3 Trial (TIMES 3) in Japan for the Treatment of Type 2 Diabetes

 

 

LYON, France & OSAKA, Japan--(BUSINESS WIRE)-- POXEL SA (Euronext – POXEL - FR0012432516), a biopharmaceutical company focused on the development of innovative treatments for metabolic disorders, including type 2 diabetes and non-alcoholic steatohepatitis (NASH) and Sumitomo Dainippon Pharma Co., Ltd (Head Office: Osaka, Japan; Representative Director, President and CEO: Hiroshi Nomura; Securities Code: 4506, First Section of TSE), announced today positive top-line Phase 3 data results for the Imeglimin TIMES 3 16-week, double-blind, placebo-controlled, randomized part of the trial for the treatment of type 2 diabetes in Japan. Referred to as TIMES (Trials of IMeglimin for Efficacy and Safety), the Imeglimin Phase 3 program in Japan includes three pivotal trials to evaluate Imeglimin’s efficacy and safety in over 1,100 patients.

 

 

Read the press release